Systemic treatment of chronic GVHD

Cellular Therapy and Transplantation

Volumn 2, Issue 6, 2009, Pages

  Schleuning, Michael ^a  

^a Zentrum für Blutstammzell und Knochenmarktransplantation   (Germany)

Author keywords

Calcineurin inhibitors; Chronic GVHD; Extracorporal photopheresis; Immunomodulatory drugs; Methotrexate; mTOR; Steroids

Indexed keywords

AZATHIOPRINE; B LYMPHOCYTE ANTIBODY; CALCINEURIN INHIBITOR; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EVEROLIMUS; HYDROXYCHLOROQUINE; IMATINIB; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; PREDNISOLONE; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ABSENCE OF SIDE EFFECTS; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; APHERESIS; CHRONIC GRAFT VERSUS HOST DISEASE; CYTOPENIA; DISEASE FREE SURVIVAL; DISEASE SEVERITY; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTRACORPOREAL PHOTOPHERESIS; GASTROINTESTINAL DISEASE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; HYPERPIGMENTATION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MEDICAL DECISION MAKING; MICROANGIOPATHY; MORBIDITY; MORTALITY; NEUROLOGIC DISEASE; NEUTROPENIA; PHASE 2 CLINICAL TRIAL (TOPIC); PHOTOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REMISSION; REVIEW; T LYMPHOCYTE ACTIVATION;

EID: 84856874363     PISSN: 1867416X     EISSN: 18668836     Source Type: Journal    
DOI: 10.3205/ctt-2009-en-000050.01     Document Type: Review

References (61)

1. Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn J Y, et al. Severity of chronic graft-versus-host disease: association with treat ment-related mortality and relapse. Blood. 2002;100(2):406-414.
2. Sullivan KM, Witherspoon RP, Storb R, Deeg HJ, Dahlberg S, Sanders JE, et al. Alternating-day cyclosporine and predniso-ne for treatment of high risk chronic graft v host disease. Blood. 1988;72(2):555-561.
3. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S, et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic infuence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988;72(2):546-554.
4. Vogelsang GB. How I treat chronic graft versus host disease. Blood. 2001;97(5):1196-1201.
5. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Therapy for chronic graft versus host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood. 2002;100(1):48-51.
6. Carnevale-Schianca F, Martin P, Sullivan K, Flowers M, Gooley T, Anasetti C, Deeg J, Furlong T, McSweeney P, Storb R, Nash RA. Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft versus host disease. Biol Blood Marrow Transplant. 2000;6(6):613-20.
7. Giaccone L, Martin P, Carpenter P, Moravec C, Hooper H, Funke VA, et al. Safety and potential effcacy of low-dose methotrexate for treatment of chronic graft versus host disease. Bone Marrow Transplant. 2005;36(4):337-341. doi: 10.1038/sj.bmt.1705022.
8. Huang XJ, Jiang Q, Chen H, Xu L, Liu D, Chen Y, et al. Low-dose methotrexate for the treatment of graft versus host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;36(4):343-348. doi: 10.1038/sj.bmt.1705034.
9. de Lavallade H, Mohty M, Faucher C, Furst S, El Cheikh J, Blaise D. Low-dose methotrexate as salvage therapy for refractory graft versus host disease after reduced intensity conditioning allogeneic stem cell transplantation. Haematologica. 2006;91(10):1438-1440.
10. Inagaki J, Nagatoshi Y, Hatano M, Isomura N, Sakiyama M, Okamura J. Low dose MTX for the treatment of acute and chronic graft versus host disease in children. Bone Marrow Transplant. 2008(6):571-7. doi: 10.1038/sj.bmt.1705922.
11. Mayer J, Krejci M, Pospisil Z, Doubek M, Janikova A, Zackova D, Racil Z, Smardova L, Navratil M, Kamelander J. Successful treatment of steroid-refractory hepatitic variant of liver graft versus host disease with pulse cyclophosphamide. Exp Hematol. 2009;37(6):767-73. pmid: 19463776.
12. Mayer J, Krejcí M, Doubek M, Pospísil Z, Brychtová Y, Tomís-ka M, Rácil Z. Pulse cyclophosphamide for corticosteroid refractory graft versus host disease. Bone Marrow Transplant. 2005;35(7):699-705. doi: 10.1038/sj.bmt.1704829.
13. Takami A, Mochizuki K, Okumura H, Ito S, Suga Y, Yamazaki H, Yamazaki M, Kondo Y, Asakura H, Nakao S. Mycophenolate mofetil is effective and well tolerated in the treatment of refractory acute and chronic graft versus host disease. Int J Hematol. 2006;83(1):80-5. pmid: 16443558.
14. Krejci M, Doubek M, Buchler T, Brychtova Y, Vorlicek J, Mayer J. Mycophenolate mofetil for the treatment of acute and chronic steroid refractory graft versus host disease. Ann Hematol. 2005;84(10):681-5. doi: 10.1007/s00277-005-1070-0.
15. Baudard M, Vincent A, Moreau P, Kergueris MF, Harousseau JL, Milpied N. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant. 2002;30(5):287-95. doi: 10.1038/sj.bmt.1703633.
16. Martin PJ, Storer BE, Rowley SD, Flowers ME, Lee SJ, Carpenter PA, Wingard JR, Shaughnessy PJ, DeVetten MP, Jagasia M, Fay JW, van Besien K, Gupta V, Kitko C, Johnston LJ, Maziarz RT, Arora M, Jacobson PA, Weisdorf D. Evaluation of mycophenolate mofetil for initial treatment of chronic graft versus host disease. Blood. 2009 May 21;113(21):5074-82. doi: 10.1182/blood-2009-02-202937.
17. Jacobsohn DA, Chen AR, Zahurak M, Piantadosi S, Anders V, Bolanos-Meade J, et al. Phase II study of pentostatin in patients with corticosteroid refractory chronic graft versus host disease. J Clin Oncol. 2007;25(27):4255-4261. doi: 10.1200/JCO.2007.10.8456.
18. Robin M, Guardiola P, Girinsky T, Hernandez G, Esperou H, Ribaud P, et al. Low dose thoracoabdominal irradiation for the treatment of refractory chronic graft versus host disease. Transplantation. 2005;80(5):634-642. pmid: 16177638.
19. Vogelsang GB, Farmer ER, Hess AD, Altamonte V, Beschorner WE, Jabs DA, et al. Thalidomide for the treatment of chronic graft versus host disease. N Engl J Med. 1992;326(16):1055-1058. pmid: 1549151.
20. Browne PV, Weisdorf DJ, Defor T, Miller WJ, Davies SM, Filipovich A, et al. Response to thalidomide therapy in refractory chronic graft versus host disease. Bone Marrow Transplant. 2000;26(8):865-869.
21. Kulkarni S, Powles R, Sirohi B, Treleaven J, Saso R, Horton C, Atra A, Ortin M, Rudin C, Goyal S, Sankpal S, Meller S, Pinkerton CR, Mehta J, Singhal S. Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft versus host disease. Bone Marrow Transplant. 2003;32(2):165-70.
22. van de Poel MH, Pasman PC, Schouten HC. The use of thalidomide in chronic refractory graft versus host disease. Neth J Med. 2001;59(2):45-9. doi: 10.1016/S0300-2977(01)00133-4.
23. Arora M, Wagner JE, Davies SM, Blazar BR, Defor T, Enright H, et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft versus host disease. Biol Blood Marrow Transplant. 2001;7(5):265-273.
24. Koc S, Leisenring W, Flowers ME, Anasetti C, Deeg HJ, Nash RA, et al. Thalidomide for treatment of patients with chronic graft versus host disease. Blood. 2000;96(12):3995-3996.
25. Lee SJ, Wegner SA, McGarigle CJ, Bierer BE, Antin JH. Treatment of chronic graft versus host disease with clofazimine. Blood. 1997;89(7):2298-2302.
26. Gilman AL, Chan KW, Mogul A, Morris C, Goldman FD, Boyer M, et al. Hydroxychloroquine for the treatment of chronic graft versus host disease. Biol Blood Marrow Transplant. 2000;6(3A):327-334. pmid: 10905770.
27. Fong T, Trinkaus K, Adkins D, Vij R, Devine SM, Tomasson M, Goodnough LT, Lopez S, Graubert T, Shenoy S, Dipersio JF, Khoury HJ. A randomized double blind trial of hydroxychloroquine for the prevention of chronic graft versus host disease after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2007;13(10):1201-6.
28. Busca A, Locatelli F, Marmont F, Ceretto C, Falda M. Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft versus host disease following allogeneic hematopoietic stem cell transplantation. Am J Hematol. 2007;82(1):45-52.
29. Chiang KY, Abhyankar S, Bridges K, Godder K, Henslee-Dow-ney JP. Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft versus host disease. Transplantation. 2002 Feb 27;73(4):665-7. pmid: 11889452.
30. Teachey DT, Bickert B, Bunin N. Daclizumab for children with corticosteroid refractory graft versus host disease. Bone Marrow Transplant. 2006;37(1):95-9. doi: 10.1038/sj.bmt.1705199.
31. Willenbacher W, Basara N, Blau IW, Fauser AA, Kiehl MG. Treatment of steroid refractory acute and chronic graft versus host disease with daclizumab. Br J Haematol. 2001;112(3):820-3. doi: 10.1046/j.1365-2141.2001.02582.x.
32. Magro L, Mohty M, Catteau B Magro L, Catteau B, Coiteux V, Bruno B, Jouet JP, Yakoub-Agha I. Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft versus host disease. Bone Marrow Transplant. 2008 Dec;42(11):757-60.
33. Olivieri A, Locatelli F, Zecca M, Sanna A, Cimminiello M, Raimondi R, Gini G, Mordini N, Balduzzi A, Leoni P, Gabrielli A, Bacigalupo A. Imatinib for refractory chronic graft versus host disease with fbrotic features. Blood. 2009 Jul 16;114(3):709-18. doi: 10.1182/blood-2009-02-204156.
34. Cutler C, Miklos D, Kim HT, Treister N, Woo SB, Bienfang D, et al. Rituximab for steroid refractory chronic graft versus host disease. Blood. 2006;108(2):756-762. doi: 10.1182/blood-2006-01-0233.
35. Ratanatharathorn V, Ayash L, Reynolds C, Silver S, Reddy P, Becker M, et al. Treatment of chronic graft versus host disease with anti CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant. 2003;9(8):505-511.
36. Zaja F, Bacigalupo A, Patriarca F, Stanzani M, Van Lint MT, Filì C, Scimè R, Milone G, Falda M, Vener C, Laszlo D, Alessan-drino PE, Narni F, Sica S, Olivieri A, Sperotto A, Bosi A, Bonifazi F, Fanin R; GITMO (Gruppo Italiano Trapianto Midollo Osseo). Treatment of refractory chronic GVHD with rituximab: a GITMO study. Bone Marrow Transplant. 2007;40(3):273-7. doi: 10.1038/ sj.bmt.1705725.
37. von Bonin M, Oelschlägel U, Radke J, Stewart M, Ehninger G, Bornhauser M, Platzbecker U. Treatment of chronic steroid-refractory graft versus host disease with low dose rituximab. Transplantation. 2008;86(6):875-9. pmid: 18813113.
38. Xia CQ, Campbell KA, Clare-Salzler MJ. Extracorporeal photo pheresis induced immune tolerance: a focus on modulation of antigen presenting cells and induction of regulatory T cells by apoptotic cells.Curr Opin Organ Transplant. 2009;14(4):338-43.
39. Greinix HT, Volc-Platzer B, Rabitsch W, Gmeinhart B, Guevara-Pineda C, Kalhs P, Krutmann J, Hönigsmann H, Ciovica M, Knob-ler RM. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft versus host disease. Blood. 1998;92(9):3098-104.
40. Seaton ED, Szydlo RM, Kanfer E, Apperley JF, Russell-Jones R. Infuence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. Blood. 2003;102(4):1217-23.
41. Bisaccia E, Palangio M, Gonzalez J, Adler KR, Rowley SD, Goldberg SL. Treating refractory chronic graft versus host disease with extracorporeal photochemotherapy. Bone Marrow Transplant. 2003;31(4):291-4. doi: 10.1038/sj.bmt.1703830.
42. Ilhan O, Arat M, Arslan O, Ayyildiz E, Sanli H, Beksac M, Ozcan M, Gürman G, Akan H. Extracorporeal photoimmunotherapy for the treatment of steroid refractory progressive chronic graft versus host disease. Transfus Apher Sci. 2004;30(3):185-7. doi: 10.1016/j.trans-ci.2004.02.003.
43. Foss FM, DiVenuti GM, Chin K, Sprague K, Grodman H, Klein A, Chan G, Stiffer K, Miller KB. Prospective study of extra corporeal photopheresis in steroid refractory or steroid resistant extensive chronic graft versus host disease: analysis of response and survival incorporating prognostic factors. Bone Marrow Transplant. 2005;35(12):1187-93. doi: 10.1038/sj.bmt.1704984.
44. Rubegni P, Cuccia A, Sbano P, Cevenini G, Carcagnì MR, Ďascenzo G, De Aloe G, Guidi S, Guglielmelli P, Marotta G, Lau- Ria F, Bosi A, Fimiani M. Role of extracorporeal photochemotherapy in patients with refractory chronic graft versus host disease. Br J Haematol. 2005;130(2):271-5.
45. www.ctt-journal.com 2009;2(6) 5
46. Couriel DR, Hosing C, Saliba R, Shpall EJ, Anderlini P, Rhodes B, Smith V, Khouri I, Giralt S, de Lima M, Hsu Y, Ghosh S, Neumann J, Andersson B, Qazilbash M, Hymes S, Kim S, Champlin R, Donato M. Extracorporeal photochemotherapy for the treatment of steroid resistant chronic GVHD. Blood. 2006;107(8):3074-80. doi: 10.1182/blood-2005-09-3907.
47. Child FJ, Ratnavel R, Watkins P, Samson D, Apperley J, Ball J, Taylor P, Russell-Jones R. Extracorporeal photopheresis (ECP) in the treatment of chronic graft-versus-host disease (GVHD). Bone Marrow Transplant. 1999;23(9):881-7.
48. Flowers ME, Apperley JF, van Besien K, Elmaagacli A, Grigg A, Reddy V, Bacigalupo A, Kolb HJ, Bouzas L, Michallet M, Prince HM, Knobler R, Parenti D, Gallo J, Greinix HT. A multicenter prospective phase 2 randomized study of extracorporeal photo pheresis for treatment of chronic graft versus host disease. Blood. 2008;112(7):2667-74. doi: 10.1182/blood-2008-03-141481.
49. Kirken RA, Wang YL. Molecular actions of sirolimus: sirolimus and mTor. Transplant. Proc. 2003;35:227S-230S. pmid: 12742500.
50. Zeiser R, Nguyen VH, Beilhack A, Buess M, Schulz S, Baker J, et al. Inhibition of CD4+CD25+ regulatory T cell function by calcineurin dependent interleukin-2 production. Blood. 2006;108:390-399. doi: 10.1182/blood-2006-01-0329.
51. Chapman JR, Valantine H, Albanell J, Arns WA, Campistol JM, Eisen H, Frigerio M, Lehmkuhl H, Marcen R, Morris R, Nashan B, Pascual J, Pohanka E, Segovia J, Zuckermann A. Proliferation signal inhibitors in transplantation: questions at the cutting edge of everolimus therapy. Transplant Proc. 2007;39(10):2937-50. doi: 10.1016/j. transproceed.2007.09.008.
52. Cutler C, Li S, Ho VT, Koreth J, Alyea E, Soiffer RJ, et al. Extended follow-up of methotrexate-free immunosuppression using siro-limus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood. 2007;109:3108-3114. doi: 10.1182/ blood-2006-09-046219.
53. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation. 2001;72:1924-1929. pmid: 11773890.
54. Schleuning M, Judith D, Jedlickova Z, Stübig T, Heshmat M, Baurmann H, Schwerdtfeger R. Calcineurin inhibitor-free GVHD prophylaxis with sirolimus, mycophenolate mofetil and ATG in allo-SCT for leukemia patients with high relapse risk: an observational cohort study. Bone Marrow Transplant. 2009;43:717-723. doi: 10.1038/bmt.2008.377.
55. Johnston LJ, Brown J, Shizuru JA, Stockerl-Goldstein KE, Stuart MJ, Blume KG, et al. Rapamycin (sirolimus) for treatment of chronic graft versus host disease. Biol Blood Marrow Transplant. 2005;11:47-55.
56. Couriel DR, Saliba R, Escalon MP, Hsu Y, Ghosh S, Ippoliti C, et al. Sirolimus in combination with tacrolimus and cortico steroids for the treatment of resistant chronic graft versus host disease. Br J Haematol. 2005;130:409-417. doi: 10.1111/j.1365-2141.2005.05616.x.
57. Jurado M, Vallejo C, Pérez-Simón JA, Brunet S, Ferra C, Bal-salobre P, et al. Sirolimus as part of immunosuppressive therapy for refractory chronic graft versus host disease. Biol Blood Marrow Transplant. 2007;13:701-706.
58. Jedlickova Z, Burlakova I, Cook A, Baurmann H, Schwerdt-feger R, Schleuning M. MTOR inhibitors for treatment of sclero dermatous chronic graft versus host disease following allogeneic stem cell transplantation. Bone Marrow Transplant. 2009;43(suppl. 1):S123(abs.).
59. Recher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood. 2005;105:2527-2534. doi: 10.1182/blood-2004-06-2494.
60. Kuppahally S, Al-Khaldi A, Weisshaar D, et al. Wound healing complications with de novo sirolimus versus mycophenolate mofetil based regimen in cardiac transplant recipients. Am.J.Transplant. 2006;6:986-992.
61. Klink A, Schilling K, Rapp K, Höffken K, Sayer HG. High overall response rate in calcineurin inhibitor-free treatment with the mTOR inhibitor everolimus in advanced extensive chronic GvHD after allogeneic stem cell transplantation. Blood. 2008;112:2210 (abs.).